Physician profile
Jennifer Ray
NPI 1962418673
$9,462.19
in general payments reported to CMS, 2019-2025
31 companies · $2,070 in 2025
The $2,070 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $625 · 2021: $805 · 2022: $1,360 · 2023: $1,822 · 2024: $1,806 · 2025: $2,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,598 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,598.19 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,944.89 | 2019-2025 | |
| Janssen Biotech, INC. | $899.94 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $795.02 | 2019-2024 | Levulan Kerastick, Winlevi, Blu-U |
| Novartis Pharmaceuticals Corporation | $784.97 | 2019-2025 | |
| Genzyme Corporation | $713.80 | 2019-2025 | |
| Lilly USA, LLC | $515.28 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $511.67 | 2023-2025 | Sotyktu |
| Amgen INC. | $492.29 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $490.95 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $403.27 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $345.38 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $195.16 | 2019-2025 | Nemluvio, Epsolay |
| Organon LLC | $190.65 | 2025 | Vtama |
| Ucb, INC. | $189.89 | 2023-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $176.21 | 2019-2025 | Targretin, Cabtreo, Duobrii |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $162.55 | 2023-2025 | Zoryve |
| Incyte Corporation | $162.48 | 2022-2025 | Opzelura |
| Strata Skin Sciences, INC. | $77.33 | 2022 | |
| Dermavant Sciences, INC. | $61.30 | 2022-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $51.81 | 2020 | |
| Genentech USA, INC. | $48.69 | 2019-2020 | |
| Almirall LLC | $44.64 | 2022-2025 | Seysara |
| Mallinckrodt Hospital Products INC. | $42.33 | 2024-2025 | Acthar |
| Epi Health, LLC | $33.01 | 2022 | |
| Mayne Pharma Commercial LLC | $28.46 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $20.29 | 2023 | Valchlor |
| Dusa Pharmaceuticals, INC. | $20.17 | 2019 | |
| Springworks Therapeutics, INC. | $18.25 | 2025 | Gomekli |
| Botanix Sb INC | $16.39 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $14.24 | 2019 | |
| Merck Sharp & Dohme LLC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.